<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374841</url>
  </required_header>
  <id_info>
    <org_study_id>IEO S513/110</org_study_id>
    <secondary_id>2009-018083-94</secondary_id>
    <nct_id>NCT01374841</nct_id>
  </id_info>
  <brief_title>Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors</brief_title>
  <official_title>Nonmyeloablative Hematopoietic Stem Cell Transplantation (SCT) for High-Risk Hematologic Malignancies With Related, HLA-Haploidentical Donors: A Phase II Trial of Immunosuppression With Cyclophosphamide Administered Before and After SCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if engraftment can be achieved safely in patients&#xD;
      with high-risk hematologic malignancies who undergo non-myeloablative transplant with&#xD;
      peripheral stem cells from Human Leukocyte Antigen (HLA) haploidentical donors with pre and&#xD;
      post-transplant cyclophosphamide as immunosuppression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is important to extend the option of nonmyeloablative, hematopoietic stem cell&#xD;
      transplantation (HSCT) for potential therapy of hematologic malignancies to patients who do&#xD;
      not have an HLA-matched donor. Almost all patients would have a related donor identical for&#xD;
      one HLA haplotype (haploidentical) and mismatched at HLA-A, B or DR of the unshared&#xD;
      haplotype. Thus far, nonmyeloablative HSCT from HLA-mismatched donors has been associated&#xD;
      with a high rate of graft failure and graft-versus-host disease (GVHD). In this protocol, we&#xD;
      will use a combination of immunosuppressive agents including cyclophosphamide administered&#xD;
      before and after HSCT to facilitate engraftment and to delete highly alloreactive T-cell&#xD;
      clones presumably involved in GVHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Donor engraftment</measure>
    <time_frame>Day +84</time_frame>
    <description>percentage of donor engraftment after 84 from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of graft versus host disease</measure>
    <time_frame>up to 200 days after the baseline</time_frame>
    <description>Incidence and severity of graft versus host disease after 200 days from the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse-related mortality</measure>
    <time_frame>Incidence and severity of graft versus host disease after 200 days from the baseline</time_frame>
    <description>incidence of non-relapse-related mortality after 200 days from the baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplant+Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with high-risk hematologic malignancies will receive hematopoietic stem cell transplantation from haploidentical donors after treatment with cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4</description>
    <arm_group_label>Stem Cell Transplant+Cyclophosphamide</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation,</intervention_name>
    <description>Hematopoietic Stem Cell Transplantation,</description>
    <arm_group_label>Stem Cell Transplant+Cyclophosphamide</arm_group_label>
    <other_name>Stem cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≤70 years old&#xD;
&#xD;
          -  Eligible diagnoses:&#xD;
&#xD;
          -  CML in AP&#xD;
&#xD;
          -  AML with high-risk cytogenetics [del(5q)/-5, del(7q)/-7, abnormal 3q, 9q, 11q, 20q,&#xD;
             21q, 17p, t(6:9), t(9;22), complex karyotypes (≥3 abnormalities)] in CR1&#xD;
&#xD;
          -  AML ≥ CR2; patients should have &lt;5% marrow blasts at the time of transplant&#xD;
&#xD;
          -  High-risk ALL defined as:&#xD;
&#xD;
        CR1 with high-risk cytogenetics t(9;22), t(8;14), t(4;11), t(1;19) for adult patients &gt;4 wk&#xD;
        to achieve CR1&#xD;
&#xD;
        ≥ CR2 Patients should have &lt;5% marrow blasts at the time of transplant&#xD;
&#xD;
          -  MDS (&gt;int-1 per IPSS) after ≥ 1 prior cycle of induction chemotherapy; should have&lt;5%&#xD;
             marrow blasts at the time of transplant&#xD;
&#xD;
          -  MM Stage II or III patients who have progressed after an initial response to&#xD;
             chemotherapy or autologous HSCT or MM patients with refractory disease who may benefit&#xD;
             from tandem autologous-nonmyeloablative allogeneic transplant&#xD;
&#xD;
          -  CLL, NHL or HD who are ineligible for autologous HSCT or who have resistant/refractory&#xD;
             disease and who may benefit from tandem autologous nonmyeloablative allogeneic&#xD;
             transplant.&#xD;
&#xD;
          -  Patients who have received a prior allogeneic HSCT and who have either rejected their&#xD;
             grafts or who have become tolerant of their grafts with no active GvHD requiring&#xD;
             immunosuppressive therapy could be enrolled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with suitably matched related or unrelated donors&#xD;
&#xD;
          -  Patients with conventional transplant options (a conventional transplant should be the&#xD;
             priority for eligible patients ≤ 50 yr of age who have a related donor mismatched for&#xD;
             a single HLA-A, -B or DRB1 antigen)&#xD;
&#xD;
          -  CNS involvement with disease refractory to intrathecal chemotherapy&#xD;
&#xD;
          -  Presence of active, serious infection (e.g., mucormycosis, uncontrolled aspergillosis,&#xD;
             tuberculosis)&#xD;
&#xD;
          -  Karnofsky Performance Status &lt; 60% for adult patients (Appendix A)&#xD;
&#xD;
          -  Patients with the following organ dysfunction:&#xD;
&#xD;
               -  Left ventricular ejection fraction &lt;35%&#xD;
&#xD;
               -  DLCO &lt;35% and/or receiving supplemental continuous oxygen&#xD;
&#xD;
               -  Liver abnormalities: fulminant liver failure, cirrhosis of the liver with&#xD;
                  evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic&#xD;
                  encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by&#xD;
                  prolongation of the prothrombin time, ascites related to portal hypertension,&#xD;
                  bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis&#xD;
                  with total serum bilirubin &gt;3 mg/dL or symptomatic biliary disease.&#xD;
&#xD;
          -  HIV-positive patients&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant (β-HCG+) or breast feeding&#xD;
&#xD;
          -  Fertile men and women unwilling to use contraceptives during and for 12 months post&#xD;
             transplant&#xD;
&#xD;
          -  Life expectancy severely limited by diseases other than malignancy&#xD;
&#xD;
          -  Patients on any other investigational drug at time of enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rocco Pastano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rocco Pastano, MD</last_name>
    <email>rocco.pastano@ieo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocco Pastano, MD</last_name>
      <phone>+390257489538</phone>
      <email>rocco.pastano@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Rocco Pastano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 1;98(12):3456-64.</citation>
    <PMID>11719388</PMID>
  </reference>
  <results_reference>
    <citation>O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-86.</citation>
    <PMID>12171484</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>High-Risk Hematologic Neoplasms</keyword>
  <keyword>Haploidentical Donors</keyword>
  <keyword>Cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

